Foreign-owned pharmaceutical entities in Russia face specific supervisory board requirements. What in-house counsel must address. Make an enquiry.
In advising foreign-owned subsidiaries operating in regulated Russian sectors, one pattern recurs with particular consistency in the pharmaceuticals space: companies that have managed their Russian corporate governance as a routine administrative matter discover – often during a Roszdravnadzor licence renewal or a group-level compliance audit – that their supervisory board arrangements are non-compliant with the specific overlay of requirements that Russian pharmaceutical regulation imposes on top of general corporate law. The gap between what Russian corporate legislation requires of a standard limited liability company and what pharmaceutical licensing rules expect of its governance structure is narrow in some respects and materially significant in others. This guide sets out the five steps a foreign-owned pharmaceutical entity should work through to establish, audit, or remediate its supervisory board position under Russian law.
Before working through the steps below, in-house counsel should confirm the following with their Russian legal team:
If your Russian pharmaceutical subsidiary is approaching a licence renewal or a group compliance review — make an enquiry: info@vetrovpartners.com |
Russian supervisory board requirements for foreign-owned Russian entities begin with the corporate law framework applicable to the specific entity form. Under Russian corporate legislation, a supervisory board (наблюдательный совет) is a mandatory governance body only in joint-stock companies (АО) where the number of shareholders exceeds a statutory threshold. In a limited liability company (ООО) – the more common vehicle for foreign-owned Russian subsidiaries in the pharmaceuticals sector – a supervisory board is not mandatory under general corporate law, but may be established voluntarily by charter or required by sector-specific regulation.
The practical consequence is that many foreign-owned pharmaceutical ООО entities operate without a formally constituted supervisory board and have not historically needed one to satisfy their corporate law obligations. This baseline position changes, however, when pharmaceutical licensing rules are layered on. Counsel should therefore establish at the outset which framework is governing: the general corporate legislation framework, the pharmaceutical licence conditions framework, or both.
For АО entities with a dispersed foreign shareholder base, the statutory supervisory board requirement is typically already met, but the composition requirements – specifically the rules on independent members and on the qualifications of persons who may serve as members in a licensed pharmaceutical entity – may not be.
Russian pharmaceutical regulation, principally under the legislation governing the circulation of medicines, imposes governance and management requirements on licensed entities that go beyond those required by general corporate law. These requirements operate at two levels.
At the first level, the licensing rules specify qualification requirements for the "responsible person" (ответственное лицо) for pharmaceutical activities – the individual who bears personal regulatory responsibility for the licensed operations. This person must satisfy prescribed pharmaceutical education and experience criteria. Where a foreign-owned entity has structured its Russian subsidiary such that governance authority (including authority over pharmaceutical operations) sits with the supervisory board rather than the general director alone, the licensing authority – Roszdravnadzor – may scrutinise the qualifications and residency of supervisory board members as part of licence condition compliance.
At the second level, pharmaceutical Good Manufacturing Practice (GMP) standards recognised in Russia, which align substantially with EAEU pharmaceutical regulation, include requirements on management responsibility, quality system oversight, and the formal allocation of authority for quality decisions. Where these functions are assigned in the subsidiary's internal governance documents to a supervisory board or its committees, those governance instruments become part of the GMP compliance record and may be examined during inspection.
The mapping exercise for in-house counsel is therefore: does your subsidiary's governance structure formally assign any pharmaceutical regulatory function to the supervisory board or to any board-level committee? If yes, that assignment creates a compliance obligation that must be satisfied in the same manner as a direct licensing condition.
The charter of a Russian subsidiary is, in practice, the most frequently overlooked source of supervisory board obligations for foreign-owned entities. Russian corporate legislation allows considerable flexibility in defining governance structures through the charter, and many Russian subsidiaries of multinational groups were established with charter provisions drafted to mirror the parent group's governance philosophy at the time of incorporation – which may have been years or decades ago.
Common charter provisions that create unexpected supervisory board obligations include: provisions requiring supervisory board approval for transactions above a threshold value (including transactions with related parties and pharmaceutical distribution agreements); provisions assigning oversight of the responsible person's performance to the supervisory board; and provisions requiring supervisory board approval for changes to the pharmaceutical quality management system. Where such provisions exist and the subsidiary has no functioning supervisory board, every such transaction or decision made without the required approval is potentially voidable under Russian civil law.
In a recent matter, the firm acted for a European pharmaceutical group conducting a pre-transaction due diligence review of a Russian distribution subsidiary, where it was identified that charter provisions had required supervisory board approval for distribution agreements above a specified value for a period of over four years during which no supervisory board had been convened. The remediation of that position required both a governance restructuring and a specific shareholders' resolution ratifying prior transactions – a process that added several weeks to the transaction timeline.
For a foreign-owned ООО subsidiary that has determined it requires a supervisory board – whether by reason of charter obligation, pharmaceutical licensing conditions, or a decision to align with group governance standards – the establishment process involves the following procedural steps under Russian corporate and registration law.
First, the charter must be reviewed and, where necessary, amended to include compliant provisions on the supervisory board's composition, quorum, decision-making procedure, and scope of authority. Charter amendments require a general meeting of participants (the foreign parent, acting as sole or majority participant), formal notarisation, and registration with the Federal Tax Service. Registration typically takes up to five business days following notarisation, though processing times may vary.
Second, the supervisory board members must be formally appointed by a resolution of the participants' general meeting. The resolution must specify each member's full name, nationality, and – for pharmaceutical-related governance functions – the qualifications basis on which they are appointed. Where foreign nationals are appointed as supervisory board members, the resolution and supporting documentation may require apostille authentication or notarised translation, depending on the country of origin of the supporting documents.
Third, if the supervisory board is to exercise any function relevant to the pharmaceutical licence or GMP compliance record, the subsidiary's internal quality management documentation should be updated to reflect the board's authority and the procedure for escalating matters to it. This documentation is part of the GMP compliance record and should be in place before the first supervisory board meeting is held.
Foreign-owned entities should note that the overall timeline from decision to operative supervisory board – including charter amendment, notarisation, registration, and documentation update – typically runs to between four and eight weeks in practice. Groups that are approaching a pharmaceutical licence renewal or a planned Roszdravnadzor inspection should not initiate this process with less than three months to spare.
Note: Under Russian corporate legislation, transactions requiring supervisory board approval that are completed without the required approval may be challenged as void or voidable by participants or, in certain circumstances, by creditors. The risk of challenge is not theoretical in the context of pharmaceutical distribution agreements with related parties, which are a common category of transaction in foreign-owned pharma subsidiaries and a focus of regulatory scrutiny.
For in-house counsel managing the governance remediation timeline ahead of a Roszdravnadzor inspection or licence renewal — make an enquiry: info@vetrovpartners.com |
Russian corporate law does not, at the general level, impose nationality or residency requirements on supervisory board members of ООО entities. However, two categories of restriction may apply in the pharmaceutical context.
First, where the supervisory board is assigned pharmaceutical regulatory functions, Roszdravnadzor has in practice taken the position that persons exercising oversight of licensed pharmaceutical activities should be identifiable and contactable within the Russian jurisdiction. This does not translate into a strict residency requirement under the applicable legislation, but it informs a practical approach: at least one supervisory board member with oversight responsibilities for pharmaceutical functions should be reachable within Russian business hours and capable of responding to regulatory requests.
Second, where the subsidiary's pharmaceutical licence was granted on the basis of management structures that included named individuals, any change in the composition of the supervisory board that could affect those structures should be notified to Roszdravnadzor as part of the ongoing licence maintenance obligation, even if no formal prior approval is required. Failure to notify material changes to management composition is a common basis for Roszdravnadzor findings during inspection.
For АО entities, the independent director requirements applicable under Russian corporate legislation should be reviewed in the context of the supervisory board composition. Where the foreign parent group's governance code requires independent directors at subsidiary level, the Russian legal requirements and the group governance requirements should be reconciled to ensure both are satisfied by the same appointment.
Establishing a supervisory board is the first step; maintaining a compliant governance record is the operational challenge. For foreign-owned pharmaceutical entities in Russia, ongoing supervisory board compliance involves three practical components.
Minutes and resolutions must be maintained in Russian and, where the group requires it, translated into the corporate working language. Russian law requires that certain corporate decisions be notarised or recorded in a specific statutory form – supervisory board resolutions approving transactions falling within the charter-defined categories are among these. In-house counsel should confirm with their Russian legal team which categories of supervisory board decision require notarised recording and build that requirement into the governance calendar.
Annual review of the charter and internal regulations is advisable in any regulated sector in Russia. Pharmaceutical legislation and Roszdravnadzor guidance are subject to periodic revision, including revisions made through the EAEU regulatory harmonisation process. What the supervisory board's authority over pharmaceutical functions looked like at incorporation may not reflect current regulatory expectations.
The firm's Corporate Governance practice conducts periodic governance health-checks for foreign-owned Russian subsidiaries, covering charter compliance, supervisory board documentation, and alignment with current regulatory requirements. For pharmaceutical sector clients, this review also covers the GMP documentation interface described in Step 2.
For background on the regulatory update context underpinning the requirements described in this guide, see our Regulatory Update on Supervisory Board Requirements and our companion Legal Framework Analysis for Foreign-Owned Entities.
To commission a governance health-check for your Russian pharmaceutical subsidiary — make an enquiry: info@vetrovpartners.com |
Q: Do all foreign-owned pharmaceutical subsidiaries in Russia need a supervisory board?
A: Not automatically. Under general Russian corporate law, a supervisory board is mandatory only for certain joint-stock company (АО) structures once a statutory shareholder threshold is met. For limited liability companies (ООО), which are the most common structure for foreign-owned Russian pharmaceutical subsidiaries, a supervisory board is not mandatory under general corporate law unless the entity's charter requires one or pharmaceutical licensing conditions make it effectively necessary. In practice, however, many ООО entities in the pharmaceutical sector have charter provisions – often drafted at incorporation without specific pharmaceutical regulatory input – that create supervisory board obligations. In-house counsel should review both the charter and any licensing correspondence before concluding that no supervisory board obligation exists.
Q: What happens if transactions requiring supervisory board approval have been completed without a functioning supervisory board?
A: Under Russian civil law, transactions that required supervisory board approval under the entity's charter and were completed without it may be voidable. The exposure depends on the specific charter provisions, the nature and value of the transactions, and whether any affected party has raised a challenge. In the pharmaceutical context, the category most commonly affected is related-party distribution agreements. The usual remediation route involves a shareholders' resolution ratifying prior transactions alongside a governance restructuring, but the availability and effectiveness of that approach is fact-specific. Early legal review is advisable before the issue surfaces in a regulatory inspection or a transaction due diligence process.
Q: How long does it take to establish a supervisory board in a Russian ООО?
A: The end-to-end process – covering charter amendment, notarisation, Federal Tax Service registration, appointment of members, and the updating of internal quality management documentation – typically takes between four and eight weeks in practice. The registration step alone may take up to five business days following notarisation, and additional time is required where foreign-national board members require apostille documentation or notarised translations. Groups with an upcoming Roszdravnadzor licence renewal or inspection should allow a minimum of three months to complete the process without schedule pressure.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry